These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 2397009)

  • 41. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
    Simpson PJ; Smith CB; Rosenthal G; Lucchesi BR
    J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome.
    Zipser RD; Kronborg I; Rector W; Reynolds T; Daskalopoulos G
    Gastroenterology; 1984 Dec; 87(6):1228-32. PubMed ID: 6593268
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes in plasma and urinary 11-dehydrothromboxane B2 in healthy subjects produced by oral CS-518, a novel thromboxane synthase inhibitor.
    Uematsu T; Takasaki W; Kosuge K; Wada K; Matsuno H; Tanaka Y; Yamamura N; Nakashima M
    Eur J Clin Pharmacol; 1993; 45(3):283-6. PubMed ID: 8276056
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of DP-1904, a new thromboxane A2 synthetase inhibitor, on guinea pig experimental asthma.
    Takami M; Takata Y; Matsumoto K; Ono S; Tsukada W
    Ann N Y Acad Sci; 1991; 629():407-9. PubMed ID: 1952565
    [No Abstract]   [Full Text] [Related]  

  • 45. Effects of DP-1904, a thromboxane synthetase inhibitor, on the antigen-induced airway hyperresponsiveness and infiltration of inflammatory cells in guinea-pigs.
    Takami M; Tsukada W
    Prostaglandins Leukot Essent Fatty Acids; 1998 Dec; 59(6):407-14. PubMed ID: 10102387
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of DP-1904, a thromboxane A2 synthase inhibitor, administered from the autologous phase on crescentic-type anti-GBM nephritis in rats.
    Nagao T; Nagamatsu T; Suzuki Y
    Jpn J Pharmacol; 1995 Jun; 68(2):137-44. PubMed ID: 7563970
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlation between pharmacokinetics and pharmacologic effects of a new imidazole thromboxane synthetase inhibitor.
    Iwata T; Mikashima H; Takamatsu R
    J Pharm Sci; 1990 Apr; 79(4):295-300. PubMed ID: 2352139
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improvement of renal function with selective thromboxane A2 synthetase inhibitor, DP-1904 in lupus nephritis.
    Yoshida T; Kameda H; Masashi A; Homma M; Ikeda Y
    Adv Exp Med Biol; 1997; 433():113-7. PubMed ID: 9561116
    [No Abstract]   [Full Text] [Related]  

  • 49. Pharmacokinetics of CGS 12970 and inhibition of thromboxane synthesis after oral administration in healthy adults.
    Martin LL; Schaffer AV; Piraino A; Linberg L; Singh K; Rakhit A; Douglas FL
    Clin Pharmacol Ther; 1991 Apr; 49(4):433-41. PubMed ID: 2015733
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetic and pharmacodynamic studies of a thromboxane synthetase inhibitor, ozagrel, in rabbits.
    Zheng NX; Sato H; Adachi I; Kanamoto I; Horikoshi I
    Biol Pharm Bull; 1995 Dec; 18(12):1738-43. PubMed ID: 8787798
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Superiority of plasma 11-dehydro-TXB2 to TXB2 as an index of in vivo TX formation in rabbits after dosing of CS-518, a TX synthase inhibitor.
    Takasaki W; Nakagawa A; Asai F; Ushiyama S; Sugidachi A; Matsuda K; Oshima T; Tanaka Y
    Thromb Res; 1993 Jul; 71(1):69-76. PubMed ID: 8367836
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The metabolic fate of the dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in rats after intravenous and oral administration. I. Disposition and metabolic profiling.
    Gerding TK; Drenth BF; Roosenstein HJ; de Zeeuw RA; Tepper PG; Horn AS
    Xenobiotica; 1990 May; 20(5):515-24. PubMed ID: 1971983
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Pharmacokinetics of sodium 4-[alpha-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoate (Y-20811), a new thromboxane synthetase inhibitor. II. Pharmacokinetics of intact drug and main metabolite in dog].
    Iwata T; Mikashima H; Isobe M; Takamatsu R; Yokobe T
    Yakugaku Zasshi; 1989 Nov; 109(11):853-7. PubMed ID: 2614667
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Pharmacokinetics of sodium 4-[alpha-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoate (Y-20811), a new thromboxane synthetase inhibitor. I. Isolation and structure elucidation of urinary metabolite in dog].
    Iwata T; Tsuruda M; Demizu K; Isobe M; Takamatsu R; Yokobe T
    Yakugaku Zasshi; 1989 Sep; 109(9):636-41. PubMed ID: 2607414
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Skin concentrations of thromboxane synthetase inhibitor after topical application with bioelastic membrane.
    Wang NZ; Urry DW; Swaim SF; Gillette RL; Hoffman CE; Hinkle SH; Coolman SL; Luan CX; Xu J; Kemppainen BW
    J Vet Pharmacol Ther; 2004 Feb; 27(1):37-43. PubMed ID: 14995965
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Concentration-dependent protein binding of a novel oral thromboxane synthase inhibitor--FCE 22,178.
    Li RC; Rossi DT; Narang PK
    J Clin Pharmacol; 1993 Oct; 33(10):933-5. PubMed ID: 8227464
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Liquid chromatographic-ultraviolet methods for furegrelate in serum and urine: preliminary pharmacokinetic evaluation in the dog.
    Lakings DB; Friis JM
    J Pharm Sci; 1985 Apr; 74(4):455-9. PubMed ID: 4039755
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Thromboxane synthetase inhibitors. II. Optical resolution of 4-[alpha-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzo ic acid].
    Tsuruda M; Shiotsuki T; Matsumoto T; Oe T
    Yakugaku Zasshi; 1989 Jan; 109(1):26-32. PubMed ID: 2732901
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of furegrelate after oral administration to normal humans.
    Lakings DB; Friis JM; Lunan CM; VanderLugt JT; Mohrland JS
    Pharm Res; 1989 Jan; 6(1):53-7. PubMed ID: 2717519
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disposition and effect of the new thromboxane synthetase inhibitor 6-(1-imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid in man.
    Tanaka M; Ono K; Hakusui H; Takegoshi T; Shiozawa T; Nii S; Shibata H
    Arzneimittelforschung; 1990 Jun; 40(6):712-5. PubMed ID: 2397009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.